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ABSTRACT
Study queStion
What is the long term efficacy of betahistine 
dihydrochloride on the incidence of vertigo attacks in 
patients with Meniere’s disease, compared with 
placebo?
MethodS
The BEMED trial is a multicentre, double blind, 
randomised, placebo controlled, three arm, parallel 
group, phase III, dose defining superiority trial 
conducted in 14 German tertiary referral centres (for 
neurology or ear, nose, and throat). Adults aged 21-80 
years (mean age 56 years) with definite unilateral or 
bilateral Meniere’s disease were recruited from March 
2008 to November 2012. Participants received placebo 
(n=74), low dose betahistine (2×24 mg daily, (n=73)), 
or high dose betahistine (3×48 mg daily, (n=74)) over 
nine months. The primary outcome was the number of 
attacks per 30 days, based on patients’ diaries during 
a three month assessment period at months seven to 
nine. An internet based randomisation schedule 
performed a concealed 1:1:1 allocation, stratified by 
study site. Secondary outcomes included the duration 
and severity of attacks, change in quality of life scores, 
and several observer-reported parameters to assess 
changes in audiological and vestibular function.
Study anSwer and liMitationS
Incidence of attacks related to Meniere’s disease did 
not differ between the three treatment groups 
(P=0.759). Compared with placebo, attack rate ratios 
were 1.036 (95% confidence interval 0.942 to 1.140) 
and 1.012 (0.919 to 1.114) for low dose and high dose 
betahistine, respectively. The overall monthly attack 
rate fell significantly by the factor 0.758 (0.705 to 
0.816; P<0.001). The population based, mean monthly 
incidence averaged over the assessment period was 
2.722 (1.304 to 6.309), 3.204 (1.345 to 7.929), and 
3.258 (1.685 to 7.266) for the placebo, low dose 
betahistine, and high dose betahistine groups, 
respectively. Results were consistent for all secondary 
outcomes. Treatment was well tolerated with no 
unexpected safety findings. Without a control group of 
patients who did not receive any intervention to follow 
the natural course of the disease, the placebo effect 
could not be accurately assessed and differentiated 
from spontaneous remission and fluctuation of 
symptoms. 
what thiS Study addS
Current evidence is limited as to whether betahistine 
prevents vertigo attacks caused by Meniere’s disease, 
compared with placebo. The trial provides information 
on symptom relief on placebo intervention which is 
relevant for the design of future studies on potential 
disease modifying treatments in patients with 
Meniere’s disease.
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Introduction
Meniere’s disease is characterised by recurrent attacks 
of vertigo, fluctuating sensorineural hearing loss, aural 
fullness, and tinnitus.1  Its histopathological hallmark 
is endolymphatic hydrops.2 3  Lifetime prevalence of the 
disease in the United States is reported as 190 per 
100 000 people, with a ratio of 1.89 women to every 
WhAT IS AlReAdy knoWn on ThIS TopIC
Acute vertigo attacks caused by Meniere’s disease greatly affect patients’ quality of 
life and perceived wellbeing
The disease’s natural history is one of remission and recurrence; because 
participants must first have active vertigo to enrol in a study, spontaneous 
improvement through regression to the mean is expected
Observational studies or low quality randomised controlled trials of low and 
moderate betahistine doses have produced contradictory results on treatment 
efficacy, and have not investigated the effect of an experimental intervention from 
the patient’s perspective with respect to vertigo attack prophylaxis
WhAT ThIS STudy AddS
Long term prophylactic treatment with betahistine dihydrochloride (at daily doses 
2×24 mg or 3×48 mg) does not change the time course of vertigo episodes related 
to Meniere’s disease compared with placebo
Placebo intervention as well as betahistine treatment showed the same reduction 
of attack rates over the study’s nine month treatment period
Reliable and valid instruments that measure subjective vertigo symptoms (in 
particular, vertigo attacks caused by Meniere’s disease) are lacking; derivation of 
definite or probable attacks caused by Meniere’s disease, on the basis of raw 
patient recordings in vertigo diaries, is methodologically challenging and requires 
prespecified rules
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man. 4 5  Annual incidence of the disease in the USA was 
15.3 per 100 000 people (age adjusted rate).6  The peak 
age of onset is during the fifth and sixth decade.7
For patients with Meniere’s disease, unpredictable 
vertigo attacks are the most important and unpleasant 
symptom. Although the disease is clinically problem-
atic and the target of several treatments, there are so far 
no validated instruments related to vertigo that are 
based on patient reported outcomes (PRO) for compre-
hensively evaluating disease severity in a clinical trial. 
Treatment should aim to stop or reduce the number and 
severity of acute attacks of vertigo, reduce or eliminate 
tinnitus, and prevent impaired vestibular function and 
hearing loss. Given the chronic nature of the disease 
and the fluctuating and episodic pattern of symptoms, 
the long term effectiveness of any prophylactic drug 
should be investigated.
Many therapeutic approaches to Meniere’s disease 
have been studied. These include a low salt diet and 
diuretics,8  intratympanic steroid application,9 10  or 
minimal invasive interventions (such as insertion of a 
ventilation tube into the tympanic membrane,11 12  endo-
lymphatic sac surgery,13  or pulsed low pressure delivery 
(using Meniett devices)).14-17  For patients who do not 
respond to these treatments, more aggressive proce-
dures can be considered, such as intratympanic appli-
cation of gentamycin,18 19  plugging of the semicircular 
canal, labyrinthectomy, or neurectomy.20-23  However, 
these interventions are irreversible and could damage 
the cochlear and vestibular organ; furthermore, a 
recent Cochrane review could not show any evidence of 
benefit in a surgical approach.24 25
Betahistine is a licensed drug for Meniere’s dis-
ease-like symptom complexes, which contains the 
active ingredient betahistine dihydrochloride (maxi-
mum daily dose 48 mg) or betahistine dimesylate (max-
imum daily dose 36 mg). Betahistine is a strong H3 
antagonist and a weak H1 agonist26  with three sites of 
action. Firstly, it increases dose-dependent cochlear 
blood flow,27  mainly via the H3 receptor as an inverse 
agonist.28  Because betahistine has a strong first pass 
effect and is metabolised in the liver into three metabo-
lites, not only betahistine but also its major metabolite 
aminoethylpyridine increases cochlear blood flow.29 
Secondly, betahistine increases histamine turnover in 
the central nervous and vestibular system, also mainly 
via the H3 receptor. Thirdly, it decreases vestibular 
input in the peripheral vestibular system, with possible 
involvement with the H3 and H4 receptors. 
How betahistine might have an effect in the prophy-
lactic treatment of Meniere’s disease is so far unknown. 
It could lead to an improvement of labyrinthine micro-
circulation, thereby rebalancing the production and 
resorption of endolymph. The drug was first registered 
in Europe in the 1970s and has been administered to 
more than 100 million patients so far. In Germany, beta-
histine is the first line treatment for Meniere’s disease in 
clinical practice, before consideration of  endolymphatic 
sac surgery or ablative gentamicin treatment.30  The 
drug is inexpensive and well tolerated, and is one of the 
most frequently prescribed drugs for Meniere’s disease 
in Europe.31 32 In the USA, betahistine is not approved by 
the Food and Drug Administration but can be easily 
obtained through US compounding pharmacies with a 
prescription.
Several clinical studies assessing the effect of beta-
histine on the vestibular system and, to a lesser degree, 
audiological symptoms suggested that the drug 
improved these symptoms.33 34  According to a Cochrane 
systematic review of betahistine for Meniere’s disease 
or syndrome, there is, however, insufficient evidence to 
indicate whether betahistine has any effect.33  So far, 
randomised controlled trials that meet high quality 
standards are lacking, either due to inadequate diag-
nostic criteria or methods,35 or because the effect of 
betahistine treatment on vertigo was assessed inade-
quately. To summarise, the limitations of the evidence 
base for preventive treatment strategies for Meniere’s 
disease include:
•	 Predominance of trials investigating short term 
effects (treatment periods of six months or less)
•	 Inclusion criteria of enrolled patients (for instance, 
no differentiation between patients with the disease 
and patients with other causes of vertigo)
•	 High dropout rates35 with potential for considerable 
attrition bias
•	 Small trials or few placebo controlled trials36
•	 Varying quality of outcome measures for assessing 
efficacy (including quality of life scores, functional 
impairment, disability, and the number and severity 
of acute attacks of vertigo).33
The dose of betahistine in these studies varied between 
16 and 72 mg per day, which might explain the differ-
ences in symptom relief observed. Even higher doses of 
up to 480 mg per day have shown benefit for severe 
cases in a small case series, suggesting a possible effect 
of high dose regimens in the treatment of Meniere’s dis-
ease.37  The drug seems to retain a good tolerability pro-
file. On the basis of many years’ clinical experience, the 
dose was successively increased to 48 mg three times a 
day, pointing towards the role of long term treatment 
(up to 12 months). This dose increase was supported by 
an open, uncontrolled, non-masked study without a 
placebo arm that compared a high dose regimen of 48 
mg three times daily with the recommended standard 
dose of 16 or 24 mg three times daily.36 This non-inter-
ventional study showed that the higher dose was supe-
rior to the lower dose, and that the treatment effect of 
betahistine on the incidence of attacks of vertigo 
became more prominent over time.
Owing to variable methodological rigour and short-
comings in previous trials including the potential risk 
of bias, the medical treatment of Meniere’s disease with 
betahistine (BEMED) trial was designed. This investiga-
tor initiated, prospective, longitudinal, multicentre, 
double blind, randomised, placebo controlled, three 
arm, parallel group, phase III superiority trial aimed to 
assess the long term prophylactic effects of betahistine 
dihydrochloride in two different doses and placebo. The 
doses and placebo were administered continuously for 
nine months, and investigators observed their effect on 
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the frequency, duration, and severity of acute attacks 
caused by Meniere’s disease, vertigo related impair-
ment of quality of life, and vestibular and audiological 
function.
The trial also aimed to ascertain the speed of effect—
that is, whether the two active doses can be distin-
guished from each other or from placebo by how quickly 
reduction in attack frequency is achieved.38 Addition-
ally, the tolerance and adverse events were examined. 
We report the prespecified efficacy and safety analyses 
at nine months for the BEMED trial.
Methods
Study population and protocol
Study participants were recruited by the outpatient diz-
ziness services in the neurology department or the ear, 
nose, and throat department of 14 German university 
hospitals. Patients were enrolled in the study from 31 
March 2008 (first patient, first visit) to 5 November 2013 
(last patient, last visit), including a three month 
 follow-up. Patients aged 18-80 years were eligible for 
enrolment if they presented with two or more definitive 
spontaneous episodes of vertigo of at least 20 minutes’ 
duration, had audiometrically documented hearing 
loss on at least one occasion, and tinnitus or aural full-
ness in the treated ear, excluding other possible causes 
of vertigo. These factors made up a diagnosis of definite 
unilateral or bilateral Meniere’s disease, fulfilling the 
criteria of the 1995 American Academy of Otolaryngolo-
gy-Head and Neck Surgery (AAO-HNS) guideline.39 Fur-
thermore, patients had to be in an active phase of the 
disease, with at least two vertigo attacks per month in at 
least three consecutive months before enrolment. 
Female patients of childbearing potential were only 
included if they had a negative serum pregnancy test 
within seven days before initiation of treatment and 
were willing to practice acceptable methods of birth 
control during treatment and for three months after 
treatment.
Exclusion criteria were diagnosis of other central or 
peripheral vestibular disorders such as vestibular 
migraine, benign paroxysmal positioning vertigo, par-
oxysmal brainstem attacks, as well as phobic postural 
vertigo. Patients were excluded if they had known con-
traindications or sensitivity to betahistine, such as 
bronchial asthma, pheochromocytoma, treatment with 
other antihistaminic drugs, ulcer of the stomach or duo-
dendum, or severe dysfunction of liver or kidney. Safety 
related exclusion criteria were severe coronary heart 
disease or heart failure, persistent uncontrolled hyper-
tension with systolic blood pressure higher than 180 
mm Hg or diastolic blood pressure higher than 110 mm 
Hg, life expectancy less than 12 months, other serious 
illness, or a complex disease that might confound treat-
ment assessment. General exclusion criteria were 
 participation in another trial with an investigational 
drug or device within the past 30 days, previous partic-
ipation in the present study, or planned participation in 
another trial. We excluded pregnant and breastfeeding 
women and women contemplating pregnancy during 
the trial from enrolment.
Written informed consent was obtained from all 
patients before initiation of the first study specific pro-
cedure. The protocol was approved by local indepen-
dent ethics committees and was performed in 
accordance with the Declaration of Helsinki and other 
applicable guidelines, laws, and regulations. The study 
was a longitudinal, multicentre, double blind, ran-
domised, placebo controlled, three arm, parallel group, 
dose defining phase III trial conducted at 14 academic 
sites throughout Germany.
The individual study duration was 12 months: nine 
months of treatment and three months of follow-up. 
Both the examinations and the study, treatment were 
performed in an outpatient setting. At the baseline visit, 
patients received their study drug treatment together 
with a paper based vertigo diary, and returned to the 
study centre at months one, four, and six; and at the 
end of the treatment period at month nine. In addition 
to these four clinic visits, five standardised telephone 
interviews were performed after postbaseline months 
two, three, five, seven, and eight, to verify compliance 
and increase protocol adherence. In particular, these 
interviews reminded patients to complete their vertigo 
diary every day and to record any treatment discontinu-
ation, change in relevant concomitant drug treatment, 
or adverse events they might have experienced in the 
meantime (which were also documented regularly on 
the case report forms during each telephone and clinic 
visit).
All patients underwent a standardised physical, neu-
rological, and neuro-orthoptic examination; peripheral 
vestibulocochlear testing; assessment of medical his-
tory (for up to five years before enrolment); laboratory 
examination; and measurement of blood pressure and 
heart rate. We also performed electronystagmography, 
including bithermal caloric irrigation to measure 
caloric nystagmus response, and pure tone audiometry. 
At each clinic visit, patients had to complete three 
self-administered questionnaires on quality of life 
aspects, and their diaries were checked for data com-
pleteness and quality of documentation to ensure 
patient comprehension of the diary items.
randomisation, concealment, and blinding
A total of 221 eligible patients at 14 study sites were ran-
domly assigned in a 1:1:1 ratio to receive either high dose 
or low dose betahistine, or placebo for nine months 
(fig 1). Each site received a pool of study medication kits 
including the treatment assignment in a sealed opaque 
emergency envelope. If a patient dropped out before 
receiving the kit, he or she was replaced by the next eli-
gible patient enrolled at the same centre. The concealed 
allocation was performed by an internet based rando-
misation schedule (https://wwwapp.ibe.med.uni-
muenchen.de/randoulette), stratified by study site. The 
fixed block size was three (starting with six), which was 
not disclosed during the trial. The random number list 
was generated by an investigator with no clinical 
involvement in the trial. Patients, clinicians, core labo-
ratories, and trial staff (data analysts, statisticians) 
were blind to treatment allocation.




Betahistine dihydrochloride tablets were over-encapsu-
lated with mannitol and aerosil as filling material. Cap-
sules containing the active ingredient were refilled from 
original pharmacy packaging into vials under sterile 
conditions and relabelled by the pharmacy of the uni-
versity hospital of the University of Heidelberg. In the 
control group, an identically appearing capsule filled 
with mannitol and aerosil but not containing any active 
ingredient was administered as placebo.
Patients were instructed to take six capsules per 
day (two capsules in the morning, two at noon, and 
two in the evening). The first drug intake started as 
soon as possible after receipt of the study medication 
kits containing the vials during the baseline visit. 
Patients assigned to the experimental arms were 
given low doses or high doses of betahistine dihydro-
chloride (Vasomotal, manufactured by Abbott 
Pharma, Hannover, Germany). A dose of 24 mg, which 
is the highest clinically admitted dose, was adminis-
tered orally two times each day to the low dose group, 
and 2×24 mg three times each day were given to the 
high dose group; both groups received treatment for 
nine months. In the low dose group, patients took one 
betahistine capsule and one placebo capsule in the 
morning; two placebo capsules at noon; and one 
betahistine capsule together with one placebo cap-
sule in the evening.
The nine month treatment duration was deemed nec-
essary and adequate to reliably assess the long term 
prophylactic effect of continuous treatment on the inci-
dence and severity of vertigo symptoms caused by 
Meniere’s disease. There were no disallowed concomi-
tant drugs used during the study except for antihista-
minic drugs, because we aimed to assess the efficacy of 
the assigned prophylactic treatment irrespective of res-
cue medication use by measuring efficacy conditional 
on real life adherence. Hence, rescue medication for 
managing of acute vertigo related symptoms such as 
vomiting or nausea could also be prescribed, because a 
possible effect on the occurrence of vertigo attacks is 
unknown.
Study outcomes and data collection
Blinded diary assessment
Participants were instructed to record acute attacks of 
vertigo related to Meniere’s disease, coexisting symp-
toms (such as aural fullness, changes in tinnitus, 
changes in hearing) and other characteristics of their 
vertigo attack. Other characteristics included time of 
onset, type of vertigo (rotatory or postural vertigo, gait 
unsteadiness, or lightheadedness), duration, and 
severity in a paper based diary for the full 12 month 
study duration. We also monitored additional symp-
toms that could occur simultaneously with attacks 
caused by Meniere’s disease and symptoms of other dis-
Assessed for eligibility (n=1450)
Randomisation (n=221)
Allocated to placebo (n=74):
  Received allocated intervention (n=74)
Allocated to low dose betahistine (n=73):
  Received allocated intervention (n=72)
  Did not receive allocated intervention
    (fear of placebo) (n=1)
Allocated to high dose betahistine (n=74):
  Received allocated intervention (n=74)
Diary information unavailable (n=15):
  Withdrawal of informed consent (n=6):
    Adverse events (n=2)
    Worsening of vertigo symptoms (n=1)
  Lost to follow-up (n=5)
  No diary (n=1)
  Dropout due to lack of ecacy (n=3)
Months 7 to 9
Diary information unavailable (n=10):
  Withdrawal of informed consent (n=3):
    Adverse events (n=1)
  Lost to follow-up (n=2)
  Dropout due to AEs (n=2)
  Dropout due to lack of ecacy (n=2)
  Refused intervention (fear of placebo) (n=1)
Diary information unavailable (n=15):
  Withdrawal of informed consent (n=1)
  Lost to follow-up (n=1)
  Dropout due to adverse events (n=5)
  Dropout due to lack of ecacy (n=4)
  Dropout due to lack of compliance (n=1)
  No diary (n=1)
  No time or study duration (n=2)
FAS (n=72):
  With diary within months 1-9 (n=67)
  No diary (n=5)
Included in sensitivity analysis based on
  data for months 7-9 only (n=57)
PP set (n=50)
FAS (n=70):
  With diary within months 1-9 (n=68)
  No diary (n=2)
Included in sensitivity analysis based on
  data for months 7-9 only (n=60)
PP set (n=54)
FAS (n=72):
  With diary within months 1-9 (n=69)
  No diary (n=3)
Included in sensitivity analysis based on
  data for months 7-9 only (n=57)
PP set (n=51)
Ineligible patients (of whom 45 were ineligible because
  they fullled 2 of the reasons below) (n=1229):
    Did not meet inclusion criteria (n=515)
    Declined to study participation (n=304)
    Did not want to stop ongoing betahistine treatment (n=93)
    Met exclusion criteria (n=204)
    Other reasons (n=158)
Fig 1 | Study flowchart, according to the consolidated standards of reporting trials (ConSort). the diagram shows 
enrolment and primary efficacy endpoints based on patient diaries, from prescreening to data collection; and the extent 
of exclusions, loss to follow-up, and completeness of diary documentation available across months one to nine. Stages 
following randomisation are allocation, follow-up, and analysis. FaS=full analysis set; pp=per protocol 
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eases with vertigo symptoms, to catching real attacks 
related to Meniere’s disease. Web appendix 1 shows a 
template of the vertigo diary.
Typically, attack data were recorded by the patients 
whenever they experienced vertigo related symptoms. 
However, owing to the complexity of vertigo symptoms, 
erroneously documented perseverative or persistent 
episodes of vertigo, and differing individual perceptibil-
ity, counting of vertigo attacks caused by Meniere’s dis-
ease is challenging.40 Therefore, all raw patient ratings 
(this is, the patient’s opinion of the occurrence of ver-
tigo episodes) were evaluated in a blinded manner by 
trained professionals (CSF; CA) at the site of the princi-
pal investigator. The decision process was performed 
according to a consensus document (unpublished stan-
dard operating procedure) before unblinding in order to 
define conclusive primary efficacy data from a clinical 
perspective on the basis of the whole attack information 
documented in the patient’s diary. In particular, since 
multiple classifications concerning the type of vertigo 
episode were documented in the original patient dia-
ries, the hierarchy displayed above was used to derive 
type specific efficacy outcomes, with rotatory vertigo 
being the most severe of four different types used to 
characterise an attack.
The primary efficacy outcome was the individual 
attack rate standardised on a 30 day interval (starting 
from timepoint 1—defined as the date of first intake, 
with the day of first study drug intake being day 1). The 
number of evaluated days was defined as the number of 
days with non-missing information about the patient’s 
vertigo status, as provided by the daily diary recordings. 
For example, a patient with 12 attacks during 75 docu-
mented days (that is, 75÷30=2.5 intervals) has the rate 
12÷2.5=4.8. The 15 undocumented days out of the pre-
specified 90 day assessment period (starting day 181, 
ending day 270) were considered as missing at 
 random.41
Secondary efficacy outcomes
Diary based secondary efficacy endpoints were the 
median duration and median severity of evaluated 
Meniere’s attacks during months seven to nine within 
the nine month treatment period. 
We measured handicap and impairment of quality of 
life due to vertigo or tinnitus with the following three 
well established self-administered questionnaires: the 
dizziness handicap inventory score based on 25 items,42 
the vestibular disorders activities of daily living 
(VDADL) score,43  and the mini-tinnitus impairment 
questionnaire score based on 12 items (MiniTF12).44 45 
The total VDADL score is defined as the median value of 
answers across all 28 questions and is thus not affected 
significantly by missing values. To deal with missing 
items for both the dizziness handicap inventory score 
and the MiniTF12 questionnaire, we derived the mean 
total scores for the dizziness handicap inventory and 
the MiniTF12 as secondary outcome variables, averag-
ing for the number of available answers. For all three 
scores, higher values reflect greater perceived disability 
and impairment of QoL. Web appendix 2 shows the defi-
nition of the total scores for the dizziness and self-as-
sessment scales.
A key secondary endpoint measured during clinic 
visits was peripheral vestibular function determined by 
electronystagmography under caloric irrigation (two 
test conditions for the right and left ear: 30°C for the 
cool irrigation, 44°C for the warm irrigation). The 
parameter of interest was the peak slow phase velocity 
(recorded in °/sec) of the caloric nystagmus response of 
the selected ear. Web appendix 2 provides the definition 
of the “selected ear”; web appendix 3 shows the trial 
protocol. Furthermore, we used pure tone audiometry 
to determine hearing loss (recorded in dB) during bone 
conduction for test conditions 250 Hz, 500 Hz, 1000 Hz, 
and 2000 Hz, and to determine the tinnitus intensity (in 
dB). Likewise, these secondary outcomes were defined 
for the selected ear.
The three quality of life scores as well as the observer 
reported secondary efficacy outcomes measured during 
clinic visits were assessed at baseline and at the nine 
month visit. Explorative, not preplanned efficacy anal-
yses were performed on specific types of vertigo spells: 
rotatory or postural attacks, and rotatory only attacks.
Safety
We assessed safety from reports of adverse events as 
well as laboratory parameters, vital signs (blood pres-
sure, pulse, height, weight, and body mass index), and 
physical or neurological examinations. Safety was 
assessed over the entire treatment period at months 
one, four, six, and nine (including adverse events 
occurring in the first three weeks after cessation of 
treatment).
hypotheses and statistical methodology
Principal analysis
The BEMED trial aimed to determine whether treatment 
with high or low dose betahistine or placebo differed in 
effectiveness. We assumed that the maximum effect 
would probably occur during the prespecified 90 day 
assessment period (months seven to nine). Our first 
idea of how to analyse the primary endpoint was to per-
form a robust comparison of the number of attacks 
observed during the last three months of the nine 
month treatment period by non-parametric tests. 
During the trial, it became apparent that dropouts and 
incomplete diary documentation created missing data 
that could not be adequately handled by the intended 
robust comparison. To deal with the missing data struc-
ture in the longitudinal individual observations, we 
used a negative binomial, generalised linear mixed 
effects model (NB GLMM) that not only yields unbiased 
parameter estimates when missing observations are 
missing at random (MAR),46  but also provides 
 reasonably stable results even when the assumption of 
MAR is violated.47 48
The NB GLMM has fixed effects for treatment group, 
time (numerical variable for months one to nine), and 
treatment by time interaction. The model contains nor-
mally distributed random intercepts and random slopes 
associated with time, as well as an offset term for the 
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log-transformed number of evaluated days within each 
30 day interval.49 The offset term quantifies the 
observed information time per 30 days and delivers the 
denominator for the attack rate.
Patients who did not provide any diary data (leading 
to zero evaluable days) were excluded from the MAR 
based primary efficacy analysis, according to an “all 
observed data approach” as proposed by White and col-
leagues.50  This approach is statistically efficient with-
out using multiple imputation techniques.51 Data 
retrieved after withdrawal of randomised study treat-
ment were also included in the analysis.
The target estimates consist of the attack decay rate 
for the placebo group (fixed effect for time) as well as 
rate ratios for both betahistine dose groups (treatment 
by time interaction) to assess whether the magnitude of 
the difference between treatment groups varies over 
time (speed of effect). This model also allows individual 
attack rates over time to be calculated. To approximate 
the robust comparison as mentioned at the beginning 
of this section, we averaged the individual attack rates 
over the prespecified assessment period (months seven 
to nine) to derive a (marginal) population based, mean 
attack rate per 30 days for each treatment arm.
The principal model was established by use of data 
from a previous open non-interventional study36 
together with statistical methodology that has been 
published elsewhere.49
Analyses of secondary outcomes
Secondary outcomes assessed during clinic visits—that is, 
both the observer-reported outcome and the quality of life 
scores, were analysed in a descriptive manner. The abso-
lute change from baseline to the nine month visit was pre-
specified as the parameter of interest. For differences 
between treatment groups, we used an analysis of covari-
ance (ANCOVA) for absolute change scores, with factor for 
treatment group and the baseline value as covariates. We 
used a closed testing approach to avoid the adjustment of 
the significance level because of multiple testing. In case 
of a high proportion of missing values at baseline or at the 
nine month visit, multiple imputation techniques based 
on chained equations (the MICE method52 53) assuming 
MAR were applied within the ANCOVA.
Both diary based endpoints (attack duration and 
severity) were reported on an ordinal rating scale by use 
of predetermined codes (codes for attack duration: 2 (1-20 
min), 3 (20-60 min), 4 (60-180 min), 5 (>180 min); codes 
for attack severity: 1 (mild), 2 (moderate), 3 (severe), 4 
(very severe)). For each patient, we calculated the median 
duration and severity of attacks within months seven, 
eight, and nine (time period of primary interest). Hence, 
only patients with a total number of evaluated days larger 
than zero across the assessment period were considered 
for analysis. To quantitatively describe treatment effects 
together with 95% confidence intervals, we applied a 
cumulative logit model based on the threshold 
approach (proportional odds model). According to the 
consensus document, the variable duration was 
 necessary and sufficient for a Meniere’s attack to be 
defined on the basis of the raw diary recordings. Hence, 
there were no missing values concerning the duration 
of an evaluated attack.
Analysis sets
Analyses were based on the intention to treat principle; 
safety analyses were done on all patients who received 
at least one dose of study drug. The full analysis set 
(FAS) population included all patients randomised (irre-
spective of whether they were treated or not), and who 
did not fail to satisfy a major entry criterion. We excluded 
patients who provided neither primary nor secondary 
efficacy data from efficacy analyses, assuming MAR. 
The per protocol set consisted of all patients from the 
FAS population who did not substantially deviate from 
the protocol; they had three characteristics. Firstly, this 
group included patients for whom no major protocol 
violations were detected (for example, poor compli-
ance, errors in treatment assignment). Secondly, they 
were on treatment for at least eight months—that is, 
more than 240 days, counting from day of first intake 
(completion of a certain prespecified minimal exposure 
to the treatment regimen). Thirdly, they provided diary 
information within the 90 day assessment period (that 
is, there was availability of measurements of the pri-
mary variable within the period of interest). Hence, 
patients who prematurely discontinued the study or 
treatment before month 7 were excluded from the per 
protocol sample.
Determination and recalculation of sample size
We planned to use non-parametric tests to assess differ-
ences in the number of attacks during the last three 
months of the nine month treatment period. The closed 
testing procedure was intended to handle multiple 
comparison issues between the three arms. A general 
difference between the three arms would be tested by a 
Kruskal-Wallis test, and if the global test was significant 
(5% level), three two-group comparisons using the 
Mann-Whitney U test would be performed (5% level). 
Therefore, determination of sample size focused on a 
two group comparison based on the U test. 
The basic effect quantity of a U test is the probability 
to achieve a better result in the experimental arm than 
in the control arm. Pilot data from an observational 
study by Strupp and colleagues36 supported the 
assumption that the probability to achieve a better 
result on betahistine than placebo is 0.75. Hence, a sam-
ple size of 21 patients in each group would have 80% 
power to detect the difference between two groups 
using a two sided Mann-Whitney U test on a 5% signifi-
cance level. Initially, a dropout rate of about 25% was 
assumed. Thus, a total of 84 patients (28 in each treat-
ment group) had to be enrolled.
This optimistic sample size approach was questioned. 
A simulation study was performed to calculate a model 
based proposal for the probability to achieve a better 
result on betahistine than on placebo. We applied the 
asinh-transformed linear mixed model of Adrion and 
Mansmann49  to simulate potential study results under 
more conservative clinical scenarios. The decay rate of 
the daily attack rate (fixed effect for time) on placebo 
the bmj | BMJ 2016;352:h6816 | doi: 10.1136/bmj.h6816
RESEARCH
7
was set to −0.06, and a treatment effect of −0.08 (treat-
ment by time interaction) was chosen. A random inter-
cept with a standard deviation of 0.8 and a measurement 
error of 0.5 was assumed. These planning figures reflect 
the data of Strupp and colleagues.36 Based on 1000 sim-
ulated samples, the probability to achieve a better result 
under betahistine than under placebo was estimated as 
0.67. Based on this target parameter, the recalculated 
sample size of 46 participants per group (138 in total) 
will have 80% power to detect the difference between 
two independent groups using a Mann-Whitney U test 
with a two sided 5% significance level (nQuery Advisor 
7.0). We assumed a dropout rate of about 37%. Hence, a 
total of 220 patients had to be enrolled in the trial. Web 
appendix 2 describes preplanned sensitivity analyses 
and additional efficacy analyses as well as the statistical 
strategies applied for multiple testing.
The study database was stored in SAS (Unix Version 
9.2, SAS Institute). Statistical analyses were performed 
using the statistical software package R version 3.1.1.54 
We used the R packages lme4 (version lme4_1.1-7) to fit 
frequentist generalised linear mixed effects models,55 56 
ordinal to fit cumulative logit models,57  and mice for 
multiple imputation techniques applied for key second-
ary efficacy outcomes.52 53 All statistical tests were two 
sided, and P<0.05 was considered significant.
Previous and concomitant drug treatments were 
coded using the World Health Organization Drug Dictio-
nary (version 1 March 2014). Medical history and 
adverse events were coded using the Medical Dictionary 
for Regulatory Activities (version 17.0).
patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for participant recruitment, or the 
design and implementation of the study. There are no 
plans to explicitly involve patients in dissemination. 
Final results will be sent to all participating sites.
Results
enrolment and subject attrition
A total of 1450 patients were screened for eligibility at 17 
outpatient sites; 221 patients were randomised at 14 
sites. The largest site was the sponsor’s site located at 
the Department of Neurology, University Hospital and 
German Center of Vertigo and Balance Disorders (DSGZ) 
in Munich, Germany. At this site, 410 patients were 
screened, and 86 of 221 patients randomised (that is, 
about 40% of all study participants). Overall, 74 patients 
were assigned to the placebo group, 73 to the low dose 
betahistine group, and 74 to the high dose betahistine 
group. Figure 1 shows the flow of participants through 
the trial together with the completeness of diary infor-
mation over the entire nine month treatment period.
Of 1450 patients, 1229 (85%) did not pass the screen-
ing stage. The most common reason was that patients 
did not meet the inclusion criteria regarding attack 
 frequency (n=255), followed by general refusal to 
 participate for no specific reasons (n=204), and con-
cerns about the protocol, especially fear of placebo 
(n=100). Some did not meet the inclusion criteria of 
definite Meniere’s disease (n=123), fulfilled exclusion 
criteria (n=173), or could not tolerate or were allergic to 
betahistine (n=31). Other patients were being treated 
with betahistine and did not want to change or stop 
treatment (n=93). In some patients, the cause of vertigo 
was not clear (n=137). Other reasons (for example, a 
desire for another treatment option such as an opera-
tion; or moving abroad) were named in 158 patients. In 
total, 45 patients were judged ineligible because they 
fulfilled two of these criteria. 
No patient prematurely terminated study participa-
tion before allocation to treatment. One patient in the 
low dose group did not receive the allocated interven-
tion because of fear of placebo. Figure 1  follows the 
CONSORT PRO reporting guideline58 and reveals that 
within the three month assessment period, 79% (174 of 
221 patients) provided attack data for the primary end-
point. In each group, a few patients did not submit any 
diaries, giving no specific reason for this. Completeness 
of the patient diaries did not differ between the three 
treatment groups.
participants’ baseline characteristics
Table 1  shows the demographic and clinical character-
istics as well as three total scores on quality of life 
assessed at the baseline visit of all 221 patients ran-
domised. Overall, about half of the randomised patients 
were female; the total age range was 21-80 years. The 
treatment groups were well balanced for demograph-
ics; clinical factors; and tinnitus related, dizziness, and 
self-assessment scores. Prerandomisation attack fre-
quency was not documented, although considered as 
an inclusion criterion. Initial evaluation of the 
post-treatment frequency of attacks caused by 
Meniere’s disease within the first 30 days of treatment 
(pseudobaseline) showed the three groups to be com-
parable at the outset (table 2). Moreover, groups were 
well balanced with regard to disease duration and age 
at onset of vertiginous symptoms (data not shown).
dosing and protocol adherence
Treatment compliance based on drug accountability 
was not calculated owing to insufficient data quality 
and a high proportion of missing data. Instead, we used 
the treatment duration (defined as the difference 
between the end of treatment and the first study drug 
intake) as a measure of treatment adherence. In the FAS 
population, mean treatment duration was 222.5 days 
(95% confidence interval 201.99 to 243.10), 225.8 (204.55 
to 246.99), and 215.8 (192.63 to 239.04) in the placebo, 
low dose betahistine, and high dose betahistine groups, 
respectively (table 2). We saw no significant difference 
between the three groups concerning treatment dura-
tion (Kruskal-Wallis test used as global testing proce-
dure; FAS P=0.824; per protocol P=0.600).
Figure 2 shows for each treatment group the time to 
withdrawal and the proportion of patients who stopped 
treatment before the day indicated on the x axis. In this 
figure, an event indicating treatment dropout was 
defined as end of treatment before day 241 (according to 
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table 1 | Baseline characteristics of intention to treat sample according to study treatment
Characteristics placebo (n=74) low dose betahistine (n=73) high dose betahistine (n=74)
demographics
Age (years)
 Mean (standard deviation) 54.5 (12.8) 56.1 (11.1) 56.1 (12.6)
 Median (range) 55.0 (22.0-76.0) 57.0 (22.0-80.0) 58.0 (21.0-79.0)
Male sex (No (%)) 35 (47) 39 (53) 35 (47)
White ethnicity (No (%))* 71 (96) 72 (99) 74 (100)
neuro-otological parameters
History of migraine headache† (≤5 years before enrolment; No (%)) 17 (23) 9 (12) 13 (18)
Audiometrically documented hearing loss (inclusion criteria; No (%))‡
 Both ears 20 (27) 24 (33) 25 (34)
 Left ear 25 (34) 21 (29) 25 (34)
 Right ear 28 (38) 28 (38) 24 (32)
Documented tinnitus or aural fullness (inclusion criteria; No (%))§
 Both ears 15 (20) 16 (22) 17 (23)
 Left ear 32 (43) 27 (37) 32 (43)
 Right ear 27 (36) 30 (41) 24 (32)
Tinnitus intensity (dB), selected ear
 Mean (standard deviation) 42.8 (22.0) 44.5 (22.8) 54.0 (19.8)
 Median (range) 42.5 (0-83.0) 46.0 (0-103.0) 59.0 (5.0-83.0)
 Missing (No (%)) 24 (32) 33 (45) 29 (39)
peak slow phase velocity (°/sec), selected ear
Cool water irrigation (30°C)
 Mean (standard deviation) 8.8 (8.3) 9.8 (11.2) 7.4 (7.3)
 Median (range) 6.0 (1.0-40.0) 6.9 (0-73.0) 5.3 (0-45.0)
 Missing (No) 9 7 10
Warm water irrigation (44°C)
 Mean (standard deviation) 9.4 (8.1) 11.7 (13.0) 9.7 (11.9)
 Median (range) 6.9 (1.0-36.0) 8.0 (0-72.0) 5.5 (0-71.0)
 Missing (No) 7 5 7
pure tone audiometry (dB hearing level), selected ear
250 Hz
 Mean (standard deviation) 29.4 (18.2) 32.8 (16.0) 29.6 (16.0)
 Median (range) 31.5 (0-80) 40.0 (0-70) 30.0 (0-75)
 Missing (No) 20 22 19
500 Hz
 Mean (standard deviation) 33.6 (20.0) 36.5 (19.2) 35.4 (19.9)
 Median (range) 37 (0-75) 41 (0-70) 37.5 (0-75)
 Missing (No) 14 15 10
1000 Hz
 Mean (standard deviation) 35.3 (20.7) 37.6 (19.7) 34.4 (21.3)
 Median (range) 39 (2-80) 40 (0-70) 30 (0-75)
 Missing (No) 11 8 9
2000 Hz
 Mean (standard deviation) 35.8 (19.9) 38.7 (19.3) 37.9 (18.5)
 Median (range) 36 (0-75) 43 (0-70) 40 (5-70)
 Missing (No) 12 8 10
quality of life scores
MiniTF, mean total score
 Mean (standard deviation) 0.765 (0.564) 0.807 (0.531) 0.733 (0.482)
 Median (range) 0.667 (0-2.000) 0.750 (0-2.000) 0.750 (0-1.833)
 Missing (No) 2 4 0
VDADL, total score
 Mean (standard deviation) 1.767 (1.352) 1.754 (1.531) 1.777 (1.070)
 Median (range) 1.000 (1.000-7.000) 1.000 (1.000-10.000) 1.000 (1.000-6.000)
 Missing (No) 1 4 0
Dizziness handicap inventory, mean total score
 Mean (standard deviation) 1.693 (0.899) 1.777 (1.007) 1.765 (0.906)
 Median (range) 1.560 (0-3.840) 1.760 (0-4.000) 1.920 (0-3.583)
 Missing (No) 2 5 0
*Three Asians in placebo group; one Asian in low dose betahistine group.
†Medical history was coded using the Medical Dictionary for Regulatory Activities: primary high level group term=headache; primary high level term=migraine headaches or headaches.
‡One patient from the placebo group did not meet the inclusion criteria. This patient was not included in the full analysis set.
§One patient from the high dose betahistine group did not meet the inclusion criteria. This patient was included in the full analysis set and per protocol set and completed the trial (treatment 
duration 267 days, study duration 12 months).
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the definition for per protocol). For example, about 10% 
of the placebo patients discontinued the assigned treat-
ment before day 50, compared with about 14% of 
patients on high dose treatment. The figure also indi-
cates that about 77% of low dose patients (versus 72% 
of high dose patients and 70% of placebo patients) were 
on treatment for at least eight months (241 days). We 
found no evidence for a differential dropout (attrition 
bias) from the administered treatment between the 
three groups (log rank test P=0.703).
primary efficacy outcome measures
An NB GLMM (negative binomial mixed effects model) 
assessed a general decline in the incidence of attacks 
caused by Meniere’s disease over the nine 30 day inter-
vals. For the FAS population, the mean attack rate for 
placebo patients was significantly lowered by the factor 
0.758 per additional 30 day interval on treatment 
(95%  confidence interval 0.705 to 0.816; P<0.001). 
We hypothesised that the assigned experimental treat-
ment (low or high dose betahistine) would make this 
overall decay rate even smaller. The corresponding esti-
mated factors, representing rate ratios compared with 
placebo, were 1.036 (0.942 to 1.140) and 1.012 (0.919 to 
1.114) for the low and high dose groups, respectively 
(table 3). We saw no evidence for a treatment by time 
interaction (global testing, likelihood ratio test P=0.759 
for FAS population; P=0.493 for per protocol sample), 
indicating no significant differences in attack rates 
across the treatment groups. 
During the 90 day assessment period, the population 
based, mean attack rate per 30 days was on average 
2.722 attacks (95% confidence interval 1.304 to 6.309), 
3.204 (1.345 to 7.929), and 3.258 (1.685 to 7.266) for the 
placebo, low dose betahistine, and high dose betahis-
tine groups, respectively (table 4).










No of attacks per 30 days
 Mean (standard deviation) 6.2 (6.9) 5.8 (4.6) 5.1 (4.5)
0.625 Median (range) 4.5 (0-37) 5.0 (0-19) 4.0 (0-23)
 Missing (No) 6 1 3
Follow-up
Treatment duration (days)
 Mean (standard deviation) 222.5 (87.5) 225.8 (89.0) 215.8 (98.8)
0.824
 Median (range) 266.5 (2.0-348.0) 269.0 (0-317.0) 269.0 (2.0-311.0)
*Pseudobaseline=data documented during the first treatment month (with day 1 being the day of first study drug 
intake). Pretreatment attack data were not available.
†One patient from the full analysis set refused to take the allocated treatment, no postbaseline data available. 
For this patient, treatment duration was set zero.
























Fig 2 | proportion and timing of patient withdrawal for all 
221 patients randomised to each treatment group. 
according to the protocol, 270 days was the preplanned 
treatment duration. an event was defined as end of 
treatment before day 241 (start of grey region), according 
to the prespecified minimum exposure to the treatment 
regimen defined as per protocol and the corresponding 
definition of a major protocol deviation
table 3 | primary efficacy analysis on full analysis set, plus use of two varying definitions of Meniere’s attacks as supportive efficacy analyses
Modelling of primary efficacy outcome
decay rate (95% Ci) 
of attacks over time
rate ratio (95% Ci)
p¶low dose betahistine v placebo high dose betahistine v placebo
Vertigo attacks evaluated* (prespecified primary outcome) 0.758 (0.705 to 0.816) 1.036 (0.942 to 1.140) 1.012 (0.919 to 1.114) 0.759
Attacks of rotatory or postural vertigo† 0.766 (0.711 to 0.826) 1.032 (0.936 to 1.138) 0.974 (0.882 to 1.076) 0.511
Attacks of rotatory vertigo‡ 0.741 (0.675 to 0.813) 1.050 (0.937 to 1.177) 0.991 (0.882 to 1.115) 0.575
Vertigo attacks evaluated* in months 7-9 (GLM) n/a§ 0.846 (0.465 to 1.533) 0.887 (0.485 to 1.625) 0.850
GLM=generalised linear model; rate ratio=determined by primary efficacy analysis based on negative binomial mixed effects model (NB GLMM), based on entire nine month treatment period 
(reference group=placebo).
*Evaluated=according to prespecified decision rules described in a consensus document.
†Considers episodes of vertigo classified as rotatory or postural. This restriction implies that evaluated episodes of vertigo classified as gait unsteadiness or lightheadedness were ignored. 
‡Only evaluated episodes of vertigo classified as rotatory (ignoring attacks classified as postural or gait unsteadiness, or lightheadedness) were considered for statistical analysis.
§Not applicable because the GLM used as sensitivity analysis does not include a time effect. The GLM is based on attacks experienced across 30 day intervals seven, eight, and nine only.
¶Likelihood ratio test used as a global test.
table 4 | Marginal mean attack rates per month over study assessment periods for each treatment group (FaS population) 
Study treatment group
population based mean attack rates (95% Ci) per 30 days
Month 7 Month 8 Month 9 average rate over months 7-9*
Placebo 2.446 (1.388 to 4.572) 2.636 (1.289 to 5.934) 3.084 (1.229 to 8.397) 2.722 (1.304 to 6.309)
Low dose betahistine 2.826 (1.439 to 5.649) 3.105 (1.329 to 7.452) 3.678 (1.260 to 10.806) 3.204 (1.345 to 7.929)
High dose betahistine 2.871 (1.752 to 5.127) 3.156 (1.670 to 6.804) 3.750 (1.623 to 10.083) 3.258 (1.685 to 7.266)
Rates were estimated from a negative binomial mixed effects model. 
*Assumption: maximal effect of intervention during the prespecified 90 day assessment period (months 7-9).
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In figure 3, the upper panels show the observed indi-
vidual profiles of monthly incidences of attacks caused 
by Meniere’s disease during the nine month treatment 
period, stratified by treatment group. The lower panels 
show the estimated individual incidences per month 
over time.
For all 221 patients randomised, a total of 5003 epi-
sodes of vertigo were evaluated according to the con-
sensus document on the basis of the raw diary entries. 
Of these evaluated vertigo episodes, 1833 (37%) could 
be classified at least as an attack of postural vertigo (P 
attack); 2633 (53%) were classified as an attack of rota-
tory vertigo (R attack) and were interpreted as the most 
severe type of vertigo attack. Furthermore, 4229 (85%) 
evaluated episodes of vertigo were documented as rota-
tory, postural, or both (RP attack). Only 237 (5%) epi-
sodes of vertigo were characterised as both an R and P 
attack.
Table 3 displays the estimated rate ratios if two alter-
native definitions of a Meniere’s disease attack were 
considered for statistical analysis. Notably, these sup-
portive efficacy analyses demonstrated the robustness 
of the key results with respect to the definition of the 
primary endpoint. If either RP attacks or R attacks of 
vertigo were considered for model based primary anal-
























































Fig 3 | profile plots of observed and estimated incidence of vertigo attacks caused by Meniere’s disease. upper panels: 
observed individual trajectories of monthly incidence of attacks over nine month treatment period (divided into nine 30 
day intervals). lower panels: estimated individual trajectories of incidence of attacks per month depending on fixed and 
random effects after fitting an nB glMM (that is, conditional estimates resulting from the longitudinal model used for the 
primary efficacy analysis). thick solid lines in lower panels (indicated by arrows)=smoothing lines with standard error 
bounds. ten patients (n=5 placebo; n=2 low dose betahistine; n=3 high dose betahistine) submitted no diary for the 
entire study period for various reasons (no specific reasons (n=1), loss to follow-up (n=3), informed consent withdrawn 
(n=4), analysis dropout due to adverse events (n=2))
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 classified as gait unsteadiness or lightheadedness), 
these retrospective analyses reflected no betahistine 
effect in a consistent way.
The primary analysis considered time courses for 
each patient in a longitudinal manner, taking into 
account patients who did not provide attack informa-
tion for the three month assessment period at the end of 
the treatment period. To check whether early analysis 
dropouts affected the main efficacy results, we did a 
preplanned sensitivity analysis to calculate attack rates 
across months seven, eight, and nine by taking into 
account only patients who provided attack information 
within the 90 day assessment period. 
The results of the generalised linear model approach 
confirmed the robustness of the longitudinal model 
applied for primary efficacy analysis (table 3). For the 
FAS population, the estimated mean attack rate per 30 
days was 2.360 (95% confidence interval 1.581 to 3.712), 
1.996 (1.321 to 3.016), and 2.094 (1.370 to 3.200) for the 
placebo, low dose betahistine, and high dose betahis-
tine groups, respectively. We saw no evidence for a dif-
ference in attack rates between the three treatment 
groups for the FAS population as well as for the per pro-
tocol set (global likelihood ratio test, FAS P=0.850; per 
protocol P=0.808).
exploratory adjusted efficacy analyses
A preplanned additional analysis to investigate centre 
effects also yielded no significant treatment by time 
interaction (P>0.100) for the number of attacks per 30 
days. Pooling of sites within the catchment area of the 
DSGZ in Munich, which recruited about 40% of all ran-
domised patients, showed no evidence of a centre effect 
(P=0.542, global likelihood ratio test comparing the 
main model with the adjusted one (pooled pseudosite 
Munich yes v no)). The overall decline of attacks over 
time in the three treatment groups was not significantly 
affected by whether a patient was recruited in a study 
centre outside of Munich or not. This finding was con-
firmed when pooling small investigator sites with fewer 
than 15 randomised patients (P=0.080, global likeli-
hood ratio test).
Adjustment for sex effect did not significantly 
improve the model used for the primary efficacy 
 analysis (P=0.202, global likelihood ratio test). Hence, 
sex did not affect the time course of Meniere’s attacks, 
nor did it affect the decline in attack rates. The main 
result of no treatment induced changes in attack rates 
was therefore confirmed.
A second prespecified adjusted analysis explored 
whether estimated treatment effects varied significantly 
between age subcategories of trial participants. How-
ever, adjustment for age (using age categories as 
defined in web appendix 2) did not significantly 
improve the model used for primary efficacy analysis 
table 5 | Cumulative logit model for ordinal secondary efficacy outcomes (attack duration 
and severity), assessed over months seven to nine (FaS population)
ordinal secondary outcomes (months 7-9) estimate (95% Ci)* p
attack duration
Treatment group
Low dose betahistine v placebo −0.594 (−1.405 to 0.218)
0.348
High dose betahistine v placebo −0.383 (−1.209 to 0.444)
Threshold coefficients†
 2 v (3, 4, 5) −1.610 (−2.291 to −0.929) —
 (2, 3) v (4, 5) −0.533 (−1.150 to 0.084) —
 (2, 3, 4) v 5 0.609 (−0.006 to 1.225) —
attack severity
Treatment group
Low dose betahistine v placebo −0.505 (−1.397 to 0.386)
0.390
High dose betahistine v placebo 0.060 (−0.815 to 0.935)
Threshold coefficients†
 Mild v (moderate, severe, very severe) −2.757 (−3.657 to −1.858) —
 (Mild, moderate) v (severe, very severe) 0.459 (−0.175 to 1.092) —
 (Mild, moderate, severe) v very severe 2.095 (1.296 to 2.893) —
*Estimated coefficients are given on the logit scale. For treatment group, placebo was used as the reference 
category. Duration codes were: 2 (1-20 min), 3 (20-60 min), 4 (60-180 min), and 5 (>180 min). Severity codes 
were: mild, moderate, severe, and very severe.
†Threshold coefficients have the interpretation of log-transformed odds ratios, as known from logistic regression.




adjusted mean change 
(95% Ci) for placebo*
adjusted treatment differences (95% Ci)*
p
low dose betahistine 
v placebo
high dose betahistine 
v placebo
quality of life scores
MiniTF, mean total score 168 0.067 (−0.049 to 0.182) −0.007 (−0.140 to 0.126) −0.016 (−0.147 to 0.114) 0.970
VDADL, total score 173 0.793 (0.525 to 1.062) −0.051 (−0.324 to 0.222) −0.064 (−0.330 to 0.203) 0.883
Dizziness handicap inventory, mean total score 170 −0.104 (−0.353 to 0.145) 0.083 (−0.165 to 0.332) −0.025 (−0.267 to 0.217) 0.666
Tinnitus intensity (dB) 87 6.824 (−0.341 to 13.990) 1.400 (−5.104 to 7.904) −3.343 (−9.744 to 3.058) 0.338
peak slow phase velocity (°/sec)
Cool water irrigation (30°C) 152 4.899 (3.407 to 6.391) −0.840 (−2.638 to 0.958) 0.102 (−1.708 to 1.912) 0.532
Warm water irrigation (44°C) 156 4.840 (3.211 to 6.470) −0.886 (−2.929 to 1.157) −0.938 (−3.013 to 1.137) 0.600
pure tone audiometry (bone conduction): hearing loss (dB)
250 Hz 113 4.746 (1.043 to 8.449) 0.332 (−3.128 to 3.792) −0.214 (−3.856 to 3.428) 0.954
500 Hz 138 4.937 (0.406 to 9.469) 1.990 (−2.639 to 6.619) −0.082 (−4.511 to 4.347) 0.597
1000 Hz 144 4.338 (−0.336 to 9.012) 2.831 (−1.932 to 7.593) 1.146 (−3.265 to 5.557) 0.474
2000 Hz 145 5.480 (1.300 to 9.661) 1.665 (−2.409 to 5.739) −0.680 (−4.746 to 3.386) 0.504
VDADL total score: absolute change in median total score analysed. Tinnitus intensity, caloric irrigation, and hearing loss assessed for the selected ear.
*ANCOVA for absolute change, with factor for treatment group (placebo used as reference category) and baseline value of the dependent variable used as a covariate. Multiple imputation 
techniques applied (MICE approach; 21 imputed datasets created). Pooled P values result from global testing (model with v without treatment group). Absolute change means difference of nine 
month value minus baseline value.
†Numbers of patients with non-missing observations for both baseline and nine month visit (FAS population: n=214).
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(P=0.771, global likelihood ratio test). This finding indi-
cated that age did not affect the decline in attack rates 
as was seen in the model used for the primary efficacy 
analysis.
attack duration and severity
The duration and severity of an attack for those patients 
with at least one evaluated attack of Meniere’s disease 
within the assessment period was analysed by a cumu-
lative logit modelling approach to compare ordinal 
duration and severity data across the study treatment 
groups. We wanted to examine whether the percentages 
of patients with attacks of a longer duration and a 
higher severity, respectively, were reduced by the 
assigned treatment. For the FAS population as well as 
the per protocol sample, the percentages of patients 
with longlasting attacks or more severe attacks did not 
significantly differ across treatment groups (duration: 
P=0.348 (FAS), P=0.515 (per protocol); severity: P=0.390 
(FAS), P=0.438 (per protocol)). The data showed that the 
experimental treatment with low dose or high dose 
betahistine did not lead to higher probabilities of 
attacks in the low categories of duration and severity, 
respectively, as compared with placebo (table 5).
patient questionnaires, and vestibular and 
audiological parameters
The three tinnitus related or vertigo specific quality of 
life scores remained fairly stable at the end of the treat-
ment period compared with the baseline scores. Table 6 
displays the results of the ANCOVA applying multiple 
imputation techniques to account for missing outcome 
data. The analysis found no evidence for between treat-
ment differences in mean change scores. Web appendix 
2 provides results of the complete case analyses. With 
regards to changes in vestibular and audiological func-
tion, no therapeutic gain of drug treatment was found. 
The efficacy of placebo treatment in tinnitus intensity, 
peak slow phase velocity during caloric irrigation with 
water at 30°C and 44°C, and pure tone audiometrically 
assessed hearing level was not significantly better than 
the efficacy of either betahistine dose. P values of more 
than 0.05 were generated by a global F test for the FAS 
population as well as the per protocol sample, with 
ANCOVA for absolute change values applied.
Clinical safety events
Table 7 summarises adverse events deemed clinically 
important. The majority of patients (>85%) in the safety 
set reported one or more treatment emergent adverse 
events (TEAEs) within the nine month treatment period, 
with no clinically relevant difference between the three 
treatment groups. The most commonly reported TEAEs 
were headache, balance disorder, nausea, nasopharyn-
gitis, feeling hot, eye irritation, and palpitations. 
 Balance disorder and nausea were more commonly 
reported in the betahistine groups than in placebo. Eye 
irritation and palpitations were more commonly 
reported with high dose betahistine than with low dose 
betahistine and placebo. Differences were, however, 
small and probably not clinically relevant.
Between 54% and 64% of patients in each treatment 
group had one or more TEAEs that were considered to 
be treatment related by the investigator: most of these 
were reported with low dose betahistine treatment 
(table 7). Most TEAEs were of mild or moderate inten-
sity. TEAEs of severe intensity were reported for 20 
(27%), 20 (28%), and 19 (26%) patients in the placebo, 
low dose betahistine, and high dose betahistine groups, 
respectively. The only adverse event of severe intensity 
reported by more than 5% of patients in any treatment 
group was headache. There were no deaths during the 
study.
Forty treatment emergent serious adverse events 
(TESAEs) were reported for 15%, 14%, and 14% of 
patients in the placebo, low dose betahistine, and high 
dose betahistine groups, respectively. TESAEs reported 
by more than one patient during the study were vertigo 
(4.1% of patients in the placebo and high dose betahis-
tine groups) and inguinal hernia and intervertebral disc 
protrusion (both 2.8% of patients in the low dose beta-
histine group). These events were all considered to be 
table 7 | Safety assessment (safety sample), by study treatment group. Frequency of clinically important adverse events 








No of deaths 0 0 0
No of patients with at least one SAE 11 (15), 21 12 (17), 14 14 (19), 21
No of patients with at least one TESAE 11 (15), 16 10 (14), 12 10 (14), 12
No of patients who prematurely terminated study because of a TEAE* 5 (7), 23 4 (6), 19 11 (15), 65
No of patients with at least one TEAE 65 (88), 426 65 (90), 429 63 (85), 427
No of patients with at least one severe TEAE 20 (27), 41 20 (28), 39 19 (26), 32
No of patients with at least one related TEAE 41 (55), 150 46 (64), 138 40 (54), 132
No of patients without any TEAE 9 (12) 7 (10) 11 (15)
Data are no (%) of patients, no of events unless stated otherwise. Percentages are based on the number of patients in the safety sample. SAE=serious 
adverse event; severe=severity reported as “severe” or missing; TEAE=treatment emergent adverse event (adverse event that started or worsened in 
severity on or after the first study drug use and within 21 days of last study drug use); TESAE=treatment emergent serious adverse event (adverse event 
that was judged to be serious by the investigator and started at or after the first use of study drug and within the gap period (21 days) after the last study 
drug use, or an adverse event that already existed before the start of that treatment but worsened during the treatment and within the gap period 
including any subsequent washout or post-treatment period). Reasonable possibility for a causal relationship=drug-event relation reported as 
“possible,” “probable,” or missing according to the adverse event CRF.
*TEAEs leading to study termination are TEAEs reported on the adverse event case report form (CRF) (yes answer to “Led to study termination”).
the bmj | BMJ 2016;352:h6816 | doi: 10.1136/bmj.h6816
RESEARCH
13
unrelated to study treatment. We saw a higher inci-
dence of drug discontinuations due to adverse events in 
the high dose betahistine group (15% v 7% (placebo) 
and 6% (low dose betahistine)). The most commonly 
reported adverse events leading to drug discontinua-
tion were tinnitus, vertigo, ear discomfort, and nervous 
system disorders, which were all more commonly 
reported with high dose betahistine than with low-dose 
betahistine treatment and placebo.
discussion
principal findings
For patients with Meniere’s disease, unpredictable ver-
tigo attacks are the most unpleasant symptom, leading 
to not just physical but also psychological strain. Clini-
cal experience and several studies have supported a 
potential beneficial effect of prophylactic drug treat-
ment with betahistine on the attacks of vertigo as well 
as on vestibular and, to a lesser degree, audiological 
symptoms.34  However, according to a Cochrane review 
of betahistine for Meniere’s disease or Meniere’s syn-
drome,33 there is insufficient evidence to say whether 
betahistine has any effect.
The key findings of the BEMED trial are as follows: 
•	 A significant decline of attack rates in each treatment 
arm was observed over the nine month treatment 
period 
•	 The effects of two different doses of betahistine could 
not be distinguished from a patient reported effect 
caused by placebo intervention in terms of the inci-
dence of attacks as well as vestibular and audiologi-
cal function and quality of life. Therefore, the results 
do not give clear evidence that patients have a rele-
vant clinical reduction in the number of attacks after 
nine months of treatment with betahistine at a daily 
dose of 48 mg or 144 mg, compared with a placebo 
(sham) intervention
•	 There were no safety concerns, and betahistine was 
well tolerated even in the high dose group of 144 mg 
betahistine per day.
results in context
Meniere’s disease is a disorder with interindividual dif-
ferences in a complex mixture of specific symptoms rep-
resented by vertigo attacks, hearing loss, tinnitus, 
pressure on the affected ear, and accompanying symp-
toms such as nausea or vomiting. The clinical course of 
the disease is cyclical and unpredictable.59  Further-
more, knowledge about the natural history and the 
underlying progression of episodes of vertigo in the 
long term is limited so far. The spectrum of symptoms 
tends to reflect the stage of the disorder. Some patients 
develop bilateral disease and non-relapsing symptoms. 
Variability also exists in the length of time required 
before symptoms improve. Perez-Garrigues and col-
leagues60 provide data that even without therapeutic 
intervention, the vertigo spells subside with time as ves-
tibular function burns out. It might be the case that for 
some BEMED trial participants, a degree of compensa-
tion had already occurred. 
Separation of the effect of treatment from the cyclical 
natural history of the disorder poses difficulties for all 
studies of Meniere’s disease. Because the natural his-
tory is one of remission and recurrence, and because 
participants must have active vertigo to enrol in a study, 
spontaneous improvement through regression to the 
mean in terms of symptom frequency and severity is 
expected, creating the illusion of a therapeutic effi-
cacy.61 62 Thus, a control group is vital to contrast the 
long term treatment effect against spontaneous 
improvement. 
The possibility of a patient experiencing an episode 
free year increases as the disease progresses.60  There-
fore, assessment of the efficacy of treatments for 
Meniere’s disease needs a randomised approach, 
including a placebo or no treatment (wait and see) con-
trol group. Following the concept of Perez-Garrigues 
and colleagues,60  the BEMED population consisted of 
patients at different stages of Meniere’s disease, which 
might be reflected by individual baseline rates as well 
as individual time slopes for decay rate of attacks (as 
displayed in the upper panels of fig 3). This consider-
ation also influenced the choice of our statistical model.
The BEMED trial is, to our knowledge, the first prag-
matic randomised controlled trial that specifically 
focuses on how betahistine prevents attacks caused by 
Meniere’s disease, taking into account different types of 
vertigo. It was designed as an investigator initiated, pro-
spective, longitudinal, multicentre, double blind, ran-
domised, placebo controlled, three arm, parallel group, 
phase III superiority trial. It specifically assessed the 
frequency, duration, and severity of acute attacks 
caused by Meniere’s disease during a nine month treat-
ment period. As secondary endpoints, the trial also 
studied the treatment effect on vertigo related 
 impairment in quality of life as well as on vestibular and 
audiological function. The BEMED trial also ascertains 
the speed of effect—that is, whether the two active doses 
can be distinguished from each other or from placebo by 
how quickly reduction in attack frequency is achieved.38 
A series of sensitivity analyses supported the consis-
tency and robustness of the BEMED efficacy results.
Studies that support a beneficial effect of betahistine 
on Meniere’s disease have been mostly observational. 
On the one hand, non-randomised studies tend to show 
larger treatment effects compared to randomised con-
trolled trials, and tend to overestimate the magnitude of 
a potential treatment effect.63 On the other hand, there is 
the question of whether bias alone can explain the large 
effect differences between observational and experi-
mental studies. There could also be a problem of exter-
nal validity for the trial under consideration. Below, we 
reconsider these aspects using the PICO approach 
(patient, intervention, comparison, outcome) to discuss 
the strengths and limitations of the BEMED trial.
Strengths and limitations
Patient population 
The BEMED trial population (n=221) was selected from 
1450 screened patients. Patients were diagnosed with 
definite Meniere’s disease according to the criteria of 
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the 1995 AAO-HNS guideline39  and the new schema for 
diagnosis of Meniere’s disease previously ratified by the 
Bárány Society,64  which are widely accepted and pro-
vide sufficient diagnostic accuracy.33  The mean 
monthly attack rate during the first month of treatment 
was about 5.7, which is considered as representative for 
patients with Meniere’s disease and being treated with 
betahistine. The population could have also included 
patients with vestibular migraine, benign paroxysmal 
positional vertigo, and secondary functional dizziness, 
which is typical for many Meniere’s disease studies.65
Intervention 
The duration of exposure to study treatment was similar 
across the three treatment groups and ranged between 
a mean of 214 and 224 days for the intention to treat 
population. About 75% of patients completed the nine 
month treatment period.
Control group
The BEMED trial decided to implement a placebo arm 
for ethical and compliance reasons. Our placebo results 
may not fully reflect Meniere’s disease’s natural history.
Outcome 
Electing the “(number of) Meniere’s attacks in a given 
time period” as the efficacy endpoint, documented by 
diaries in the patients’ natural environment (PRO), runs 
the risk of having missing or inaccurate information 
compared with objective measurements such as audio-
gram or questionnaires. In previous trials, the fre-
quency of vertigo spells was mainly documented by a 
symptom report card using a Likert scale of 0 (“no ver-
tigo”) to 4 (“worst vertigo attack ever”) to characterise a 
vertigo symptom and to perform a vertigo control cate-
gorisation as a simple and convenient summary statis-
tic of a patient’s vertigo experience.15
The BEMED trial used a more complex vertigo symp-
tom diary as an instrument to enable the patient to dif-
ferentiate between several types of vertigo feelings to 
consider the multifaceted nature of symptoms in 
Meniere’s disease. To establish efficacy or effectiveness 
from a patient’s perspective, there are no reasonable 
alternatives to patient diaries that might be superior to 
alternative PROs, such as self-assessment scales or dis-
ease specific and validated quality of life scores that 
reflect fluctuations of disease severity over time. Deriva-
tion of definite or probable Meniere’s attacks based on 
the original daily patient recordings obtained by paper 
diaries is methodologically challenging.
Other studies have used quality of life scores, func-
tional impairment, and disability instruments. In the 
BEMED trial, these PROs were implemented as second-
ary endpoints. A wide spectrum of efficacy endpoints is 
needed to measure any treatment related effect, 
because it is not known how the complex symptom 
clusters are modified by the treatment.
Generalisability to other populations 
These results are valid for patients with definite unilat-
eral or bilateral Meniere’s disease who had at least two 
monthly vertigo attacks in the three months before 
enrolment and who would receive betahistine as first 
line treatment, irrespective of whether they had 
received betahistine before. The results might not hold 
for patients with other vestibular disorders or taking 
higher doses of betahistine.
preliminary implications and recommendations for 
clinical practice, and future research
We presented the primary results of the BEMED trial 
and articulated open questions that might guide future 
studies on treatment options in Meniere’s disease (for 
example, planning figures for sample size calculation). 
Several aspects of our design and experiences during 
the trial might also be relevant for clinical trials of other 
vertigo diseases that cause recurring attacks of sponta-
neous vertigo, such as vestibular migraine or vestibular 
paroxysmia, as well as for treatment and prevention of 
acute episodes of vertigo.
Further long term randomised, placebo controlled 
trials with higher betahistine doses than examined in 
this trial could be considered to confirm or disprove our 
findings and explore the potential prophylactic capaci-
ties of betahistine for Meniere’s disease. Clinical 
research should also focus more specifically on identi-
fying predictors for betahistine treatment success, to 
broaden knowledge of this challenging field, and ulti-
mately improve patients’ quality of life. Additionally, 
reliable and valid instruments should be developed to 
assess self-reported vertigo symptoms (in particular, 
vertigo attacks associated with Meniere’s disease). The 
definition of definite or probable Meniere’s attacks 
based on the raw patient recordings documented by 
paper diaries requires the development of prespecified 
rules for outcome derivation, and specific approaches 
to handle such complex PRO data. 
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